Bi-specific T-cell engager

Source: Wikipedia, the free encyclopedia.
Structure of a BiTE. VH: Heavy chain variable regions. VL: Light chain variable regions. Different specificity is marked with different colours and shapes. The arrows point from N- to C-terminus.

Bi-specific T-cell engagers (BiTEs) are a class of artificial

cytotoxic activity, against cancer cells. BiTE is a registered trademark of Micromet AG (fully owned subsidiary of Amgen Inc).[1]

BiTEs are

kilodaltons. One of the scFvs binds to T cells via the CD3 receptor, and the other to a tumor cell via a tumor specific molecule.[2][3]

Mechanism of action

A BiTE linking a T cell to a tumor cell.

Like other bispecific antibodies, and unlike ordinary monoclonal antibodies, BiTEs form a link between T cells and tumor cells. This causes T cells to exert

MHC I or co-stimulatory molecules. These proteins enter tumor cells and initiate the cell's apoptosis.[2][4]

This action mimics physiological processes observed during T cell attacks against tumor cells.[4]

BiTEs in clinical assessment or with clinical approvals

Several BiTEs are currently in preclinical and clinical trials to assess their therapeutic efficacy and safety. [5]

Blinatumomab

Main article: Blinatumomab

Blinatumomab links T cells with CD19 receptors found on the surface of B cells. The Food and Drug Administration (US) and the European Medicines Agency approved this therapy for adults with Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia.[6]

Glofitamab

Main article: Glofitamab

It is a bispecific CD20-directed CD3 T-cell engager. It was approved for medical use in Canada in March 2023, in the United States in June 2023, and in the European Union in July 2023.

Mosunetuzumab

Main article: Mosunetuzumab

Bispecifically binds CD20 and CD3 to engage T-cells. Mosunetuzumab was approved for medical use in the European Union in June 2022.

Solitomab

Main article: Solitomab

Solitomab links T cells with the

EpCAM antigen which is expressed by colon, gastric, prostate, ovarian, lung, and pancreatic cancers.[7][8]

Talquetamab

Main article: Talquetamab

Tarlatamab

Main article: Tarlatamab

Tarlatamab has shown promise for previously treated small cell lung cancer.[9]

Tebentafusp

Main article: Tebentafusp

After clinical trials, in January 2022, the

gp100 peptide) for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.[10]

Further research

Utilizing the same technology,

MCSP specific BiTEs) and acute myeloid leukemia (with CD33 specific BiTEs) can be targeted.[11] As of 2008, research in this area is active.[11]

Another avenue for novel anti-cancer therapies is re-engineering some of the currently used conventional antibodies like

EGF receptor), using the BiTE approach.[12]

As of 2009[update], BiTEs against

CD66e and EphA2 are being developed as well.[13]

References

  1. ^ "US Trademark registration no. 3,068,856, serial number 78/040,636". US Patent and Trademark Office.
  2. ^ a b Helwick, Caroline (1 June 2008). "Novel BiTE antibody mediates contact between T cells and cancer cells". Oncology NEWS International. 17 (6).
  3. ^ Rüttinger, D.; Zugmaier, G.; Nagorsen, D.; Reinhardt, C.; Baeuerle, P. A. (2008). "BiTE-Antikörper: Durch Bispezifität T-Lymphozyten gegen Tumorzellen richten" [BiTE antibodies: Directing T lymphocytes against tumor cells by bispecifity]. Journal Onkologie (in German) (4).
  4. ^ a b "BiTE Antibody Platform". Micromet Inc.
  5. S2CID 227100306
    .
  6. S2CID 214779717
    .
  7. S2CID 25568468
    .
  8. PMID 30221040
    .
  9. ISSN 0028-4793
    .
  10. ^ Research, Center for Drug Evaluation and (January 26, 2022). "FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma". FDA.
  11. ^ a b Kischel, R; et al. (2008). "Characterization in primates of MCSP- and CD33-specific human BiTE antibodies for treatment of Melanoma and AML" (PDF). Proc Am Assoc Cancer Res. 99. Abs 2404. Archived from the original (PDF) on 2011-07-19.
  12. ^ Lutterbuese, R; et al. (2008). "Conversion of cetuximab, panitumumab, trastuzumab and omalizumab into T-cell-engaging BiTE antibodies creates novel drug candidates of high potency" (PDF). Proc Am Assoc Cancer Res. 99. Abs 2402. Archived from the original (PDF) on 2011-07-19.
  13. PMID 19509221
    .

Further reading
Retrieved from "https://en.wikipedia.org/w/index.php?title=Bi-specific_T-cell_engager&oldid=1216397838"